Sartorius Stedim Biotech SA (DIM.PA) stock: key figures, P/E, revenue and dividend

Health Care · France · ISIN FR0013154002

Price

216.40 EUR

Market cap

21.05 bn EUR

P/E (2025)

79.28

P/S (2025)

7.10

Dividend yield

0.32 %

Net margin

8.93 %

Return on equity (ROE)

6.48 %

Return on assets (ROA)

3.31 %

Sartorius Stedim Biotech SA financials

Fiscal year	2024	2025
Revenue	2.78 bn EUR	2.97 bn EUR
Gross profit	1.21 bn EUR	1.35 bn EUR
Operating income	396.00 m EUR	538.10 m EUR
EBIT	370.00 m EUR	549.00 m EUR
Net income	175.00 m EUR	265.00 m EUR
Diluted EPS – continuing operations	1.81 EUR	2.73 EUR

Full history since 1997, charts and your own formulas

This page shows the last two fiscal years. After free sign-up you get the full income statement, balance sheet and cash flow, price and dividend charts, your own formula metrics and a stock screener covering more than 8,000 companies.

About Sartorius Stedim Biotech SA

Sartorius Stedim Biotech S.A. engages in the production and sale of instruments and consumables for the biopharmaceutical industry worldwide. The company offers various products, such as cell lines; cell culture media; bioreactors; reagents; advanced therapies; and a range of products for separation, purification, and concentration processes, as well as products and systems for storage and transportation of intermediate and finished biological products. It also provides fluid management services; biolayer interferometry instruments; microbiology testing, sterility testing, and air monitoring instruments; pipette products; sensors and analyzers; screening instruments; biomolecule analysis tools; batch liquid chromatography systems; lab data and fleet management software; live cell imaging and analysis; surface plasmon resonance solutions; water purification systems; and weighing products. In addition, the company offers data analytics software; process automation platform and software; and transfection reagents and plasmid DNA solutions. The company has a collaboration with Bio Usawa Biotechnology, Ltd. focusing on developing and manufacturing monoclonal antibodies in Sub-Saharan Africa to tackle oncology, diabetes-induced eye diseases, infectious diseases, and autoimmune conditions. It serves manufacturers of medications, vaccines, food, and chemicals, as well as research and development laboratories. The company was incorporated in 1978 and is headquartered in Aubagne, France. Sartorius Stedim Biotech S.A. is a subsidiary of Sartorius AG.

More stocks

All stocks →

Not investment advice. All data without warranty, price as of 14.10.2026. Details in the risk notice.